TheraCryf plc (TCF)- ShareSoc seminar

TheraCryf is the clinical stage drug development company focussing on brain disorders. The Company has a broad clinical and preclinical pipeline in indications including addiction, anxiety, fatigue, narcolepsy, glioblastoma* and neurodevelopmental disorders (*orphan indication). Its strategy is to generate compelling data sets to preclinical and/or clinical proof of concept and partner its clinical programmes with mid-size to large pharma for larger trials and commercialisation. It also has industry partnerships with companies including Stalicla SA, in neurodevelopmental disorders. Presenters: Dr Huw Jones, CEO Huw has over 30 years’ experience of leadership roles in public and private R&D-based companies within the biotechnology and pharmaceutical sector, with a particular focus on preclinical and clinical drug development, dilutive and non-dilutive financing and business development. Most recently he was a Non-executive Director of Ixaka Ltd and Chairman of Chronos Therapeutics Ltd. Huw is a non-executive Director of biotech industry body OBN. Huw holds a PhD in pharmacology from the University of Birmingham, UK Dr Helen Kuhlman, COO Helen has over 20 years’ experience in life science beginning her career as a research scientist at Cambridge Antibody Technology and Domantis, before transitioning into strategy and business development roles. She has been an active proponent of the UK biotech innovation ecosystem, leading the creation and delivery of the £180m Biomedical Catalyst competitive grant scheme, whilst at Innovate UK. In addition to her role in TheraCryf she is an Operating Advisor with SymBiosis Capital Management, a US based healthcare focused venture fund, and an independent board member of the University Commercialization Executive Board at the University of Bath.